Medical Affairs Fundamentals and the Role of Medical Affairs in the Life Sciences Industry
What this domain tests
This section examines how medical affairs (MA) is positioned inside a biopharma or device company, what its sub-functions do, and why it is deliberately separated from commercial. Expect questions on the non-promotional mandate, lifecycle activities, medical review and sign-off of materials, and transparency obligations.
Core rules
- MA is science-led and non-promotional: no sales targets, no incentive tied to prescribing, and no proactive discussion of unapproved uses.
- Sub-functions usually include field medical (MSLs), medical information, medical communications and publications, medical education grants, HEOR, evidence generation, and the medical interface to pharmacovigilance and regulatory.
- Medical review: promotional and non-promotional materials must be accurate, fair and balanced, substantiated, consistent with the approved label, and signed off before use.
- Lifecycle: pre-launch covers evidence-gap analysis, KOL mapping and disease-state education; launch covers scientific exchange; post-launch covers real-world evidence and lifecycle expansion.
- Transparency: transfers of value to HCPs and organizations are reportable (US Open Payments; EFPIA disclosure code).
Worked example
A sales director asks an MSL to brief the sales force on off-label dosing so representatives can "handle objections". An MSL may respond to an unsolicited prescriber question about off-label use through the proper channel, but training a promotional team on off-label use for use in sales conversations converts the activity into promotion of an unapproved use. The MSL should decline, escalate to medical leadership, and route prescriber questions to medical information. "The data are accurate" is not a defence.
Traps that cost marks
- Treating MSLs as a sales-support channel, or accepting sales targets for field medical.
- Believing accurate off-label information can be promoted because it is "scientific".
- Forgetting that medical review precedes, not follows, first use of a material.